The most preferred model derived from a population of patients with metastatic RCC treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy followed the IMDC (International Metastatic RCC Database Consortium) model. Here, KDR is linked to renal cell carcinoma.